Brief: Immune Therapeutics Says Kenya Pharmacy & Poison Board Filed Co's NDA For Lodona, Thereby Accepting NDA For Full Review
26/04/2018 13:55
April 26 (Reuters) - Immune Therapeutics Inc IMUN.PK :
* IMMUNE THERAPEUTICS SAYS KENYA PHARMACY & POISON BOARD
FILED
CO'S NDA FOR LODONA THEREBY, ACCEPTING NDA FOR FULL REVIEW
Source text for Eikon: ID:nGNXbT3jB4
Further company coverage: IMUN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biostax
See all newsBrief: Biostax Corp Announces Voluntary Delisting From Otc Pink Market And SEC Deregistration
Brief: Biostax Corp. And Statera Biopharma Inc Reach Mutually Beneficial Dispute Settlement And Amended License Agreement Providing Clearer Clinical And Commercial Pathways For Both Companies
Brief: Immune Therapeutics Inc Announces Management Change
Brief: Statera Biopharma And Immune Therapeutics Inc. Announce Strategic Agreement For Rights To Low Dose Naltrexone
Brief: Immune Therapeutics Today Announces Appointment Of Michael Handley As Its New Chief Executive Officer And Member Of The Board Of Directors